Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Malonic aciduria

Orpha number ORPHA943
Synonym(s) Malonyl-CoA decarboxylase deficiency
Prevalence <1 / 1 000 000
Inheritance Autosomal recessive
Age of onset Childhood
ICD-10
  • E72.8
ICD-O -
OMIM
UMLS
  • C0342793
MeSH
  • C535702
MedDRA -
SNOMED CT
  • 124594007
  • 361203007

Summary

Malonic aciduria is a metabolic disorder caused by deficiency of malonyl-CoA decarboxylase (MCD). It is a very rare disorder that has been described in less than 20 patients. This condition usually presents in early childhood and the manifestations are variable. The majority of patients are developmentally delayed with other features that include hypotonia, seizures, hypoglycaemia, metabolic acidosis, cardiomyopathy and diarrhoea. The disease is caused by mutations in the malonyl-CoA decarboxylase gene (MLYCD, chromosome 16q24) and is inherited as an autosomal recessive trait. The MCD enzyme is involved in the degradation of malonyl-CoA and it appears that inhibition of fatty acid synthesis as a result of malonyl-CoA accumulation is responsible for at least some of the clinical manifestations of the disorder. The diagnosis of malonic aciduria can be made by detecting elevated levels of organic acids (in particular malonic and methylmalonic acid) in the urine and high levels of malonylcarnitine in the blood. The diagnosis is confirmed by demonstrating reduced enzyme activity in cultured skin fibroblasts. Screening of newborns may be possible through detection of elevated blood levels of malonylcarnitine using electrospray ionisation tandem mass spectrometry (ESI-MS/MS). Identification of the MLYCD gene mutation may also be useful for diagnosis and for genetic counselling. Prenatal screening is theoretically possible through enzyme or DNA analysis of amniocytes or chorionic villus samples. The principle treatment is dietary, with patients being recommended to follow a low fat/high carbohydrate diet. Carnitine supplements may also be recommended. The prognosis for patients is variable but the disease can be lethal in the neonatal period.

Expert reviewer(s)

  • Pr Pascale DE LONLAY

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.